chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vertigo; sore neck starting that day and continues currently; site inflammation; chills; nausea; muscle aches; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 47 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 12Aug2021 18:00 (Lot number: FD8448) at the age of 47 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Chronic bronchidis" (unspecified if ongoing); "Allergy: Penicllin" (unspecified if ongoing), notes: Allergy: Penicllin. Concomitant medication(s) included: IBUPROFEN. Past drug history included: Zyban, reaction(s): "known allergies: zyban", notes: known allergies: zyban. The following information was reported: VERTIGO (non-serious) with onset 12Aug2021 12:30, outcome "not recovered", described as "Vertigo"; NECK PAIN (non-serious) with onset 12Aug2021 12:30, outcome "not recovered", described as "sore neck starting that day and continues currently"; INFLAMMATION (non-serious) with onset 12Aug2021 12:30, outcome "recovered" (13Aug2021), described as "site inflammation"; CHILLS (non-serious) with onset 12Aug2021 12:30, outcome "not recovered", described as "chills"; NAUSEA (non-serious) with onset 12Aug2021 12:30, outcome "recovered" (13Aug2021), described as "nausea"; MYALGIA (non-serious) with onset 12Aug2021 12:30, outcome "not recovered", described as "muscle aches". Therapeutic measures were not taken as a result of vertigo, neck pain, inflammation, chills, nausea, myalgia.  Additional information: Patient has not been vaccinated prior to 4 weeks of vaccination.  Follow-Up (01Sep2021): Follow-up attempts are completed. No further information is expected.  No follow-up attempts are possible. No further information is expected.
Mom states child broke out in hives. Mom denies any problems with breathing. Instructed to call doctor's office and take to doctor's office to get checked. Prior to giving vaccine client with rash to face noted stated had fever of 101 on 5-21 denies fever within lasted 24 hours. States hives to face and states are lessened.
pt devel hives back, arms & chest 6" p/inj;mom used calamine & DPH w/resolution of hives;24hr later hives appeared on arms, legs & ears;hives have not resolved cont w/DPH;
Patient received vaccinations on 05/23/05 at 9:42 am. She received a DTaP and IPV vaccine IM in her left deltoid and one MMR SQ above the left elbow. The next afternoon (5:00 PM) her mother said she noticed the arm was becoming hard, swollen, red and hot, especially in the area of the DTaP vaccination. She did not contact a doctor because she said it takes too long to get an appointment but treated her with Mortin. Monday morning, she brought the child back to the clinic. By Monday, the redness, swelling and warmth had moved down to the top surface of her forearm and Mom stated that it was much better than it had been on Friday and Saturday, when there was a larger painful, red, swollen area on the deltoid. Mom said this was the first time patient has had a reaction and none of her two siblings have experienced one. She has no other known allergies. Mom said she has not received any more vaccines than the ones listed on the card: the recommended four DTaP ( the last in April 2001), three IPV (the last in October 2000) and one MMR (April 2001). We told her to watch patient and call her doctor if she had any more concerns or problems.
Nodes under her left arm, mild neck pain. The nodes stayed for 5 days and were extremely painful.
DRUG DOSE ADMINISTRATION INTERVAL TOO SHORT; This spontaneous report received from a patient concerned a 76 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: rheumatoid arthritis. The patient received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, intramuscular, batch number: unknown, expiry: unknown) dose not reported, 1 total, administered on an unspecified date for covid-19 prophylaxis. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  It was unknown whether the adverse event were reported following vaccination with covid-19 vaccine ad26.cov2.s (dose number in series 1). The patient received non-company suspect drug included: adalimumab (Humira) (solution for injection in pre-filled pen, subcutaneous, batch number: 1160836, expiry: unknown) 40 mg, 1 time every 2 weeks, (1 in 1 Once) from 22-JUL-2022 for rheumatoid arthritis. The patient received Moderna covid-19 vaccine(elasomeran) (dose number in series 2) (form of admin not reported, route of admin: intramuscular, batch number: unknown, expiry: unknown) dose not reported, once, administered on an unspecified date for covid-19 prophylaxis. On 22-JUL-2022, the patient experienced drug dose administration interval too short (dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable; dose of adalimumab was not changed; and action taken with elasomeran was not reported. The patient recovered from drug dose administration interval too short on 22-JUL-2022. This report was non-serious.
This is a spontaneous report from a contactable consumer (patient). A 62-year-old male patient received the second dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# EW0164), at the age of 62, via an unspecified route of administration, left arm, on Apr 13, 2021, single dose, for COVID-19 immunisation. Medical history and concomitant medications not reported. The patient previously took the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# EP6955), via an unspecified route of administration, left arm, on Mar 23, 2021, single dose, for COVID-19 immunisation. Prior to the vaccination, patient was not diagnosed with COVID-19. The patient did not receive any vaccines within four weeks prior to the vaccination. On Apr 14, 2021, patient experienced occasional cough, muscle aches, low fever, headache and general malaise. The events did not result in doctor/other healthcare professional office/clinic visit,  emergency room/department or urgent care. Therapeutic measures not taken as a result of the events. Since the vaccination, patient has not tested for COVID-19. The outcome of the occasional cough, muscle ache, low fever, headache and general malaise recovered on an unknown date in Apr 2021. No follow-up attempts needed. No further information expected.
This case was reported by a other health professional via call center representative and described the occurrence of fever in a 60-year-old female patient who received SHINGRIX. In December 2017, the patient received the 1st dose of SHINGRIX. In December 2017, 1 day after receiving SHINGRIX, the patient experienced fever and myalgia. On an unknown date, the outcome of the fever and myalgia were recovered/resolved. The reporter considered the fever and myalgia to be probably related to SHINGRIX. Additional information was reported as follows: This case was reported by the medical assistance for her hair dresser. The age at vaccination was not reported and it could be 59 or 60 years. The reporter believed that, the patient received SHINGRIX on an unknown day after she received SHINGRIX and the symptoms were lasted for 3 days due to which she was unable to go to work. Till the time of this reporting, the patient did not received her second dose. The reporter did not have any further patient or product details like initials, date of birth, lot and expiration.
Information has been received from health worker (Certified Medical Assistant) referring to an unspecified number of unspecified patients who on unknown dates received doses of oral, ROTATEQ (lot#, expire date, dose were unspecified), that underwent a supported temperature excursion. No adverse experiences reported. Additional information has been requested.
31-year-old gentleman was getting his first moderna vaccine for COVID-19 this morning when he started to have an allergic reaction and swelling of his uvula.  He has a history of a tree nut allergy.  He carries epinephrine injection.  He received epinephrine injection as well as Benadryl around 11:45 AM today.  He states since then symptoms have been improved significantly.  No difficulty breathing.  No itching.  Patient states symptoms have significantly improved since arrival in the ED today.  Patient was brought here by EMS for treatment.
Headache, fever 102, muscle aches, joint pain, severe fatigue. Given fever reducer, increase fluids, rest since onset less than 24 hours. Will seek medical care if fever continues or symptoms do not improve.
On Oct. 12, stores received an internal Urgent Removal Notice regarding Pfizer COVID-19 Vaccine- Pediatric 5-11 Years Tris-sucrose, Lot #FL2757 with manufacturer?s expiration date of Sept. 30. Information has been received from the manufacturer indicating that stability data supports the use of this product through Oct. 19.  What I need to do:  Administration data from organization indicates your location administered doses of the affected lot after the Sept. 30 expiration date but on or before Oct. 19. For doses administered between Oct. 1 and Oct. 19, with manufacturer data to support the stability and efficacy, revaccination is not indicated, and patient notification is not required. Any dose administered on or after Oct. 1 must be reported in organization and VAERS.
No adverse event; Dose administered after manufacturer date of expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after manufacturer date of expiry) and NO ADVERSE EVENT (No adverse event) in a 13-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047C22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 28-Mar-2023, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 28-Mar-2023,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered after manufacturer date of expiry). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered after manufacturer date of expiry) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Dose administered after manufacturer date of expiry).    Patient did not reported any allergy or disease. Patient did not receive any other vaccines in the 4 weeks prior to COVID-19 vaccine. Concomitant medication details not reported by the reporter. Treatment details was not reported by the reporter.
noc of vax pt started grunting progressed to high pitched scream for approx 15 min;turned white then returned to nl;
Breakthrough case admission after 3 vaccines Pfizer 4/6/21 lot# Ew0150;  PFizer 4/27/21 lot# Ew0172  Pfizer 12/30/21 lot# FL3198
pt both legs swelled from groin to ankle p/last vax; no fever or reddness; sx lasted 1 day; was ok in AM; not seen by MD;
Administered 5/22/09; on Sunday, 5/24/09 Pt developed papular rash on upper back and chest, with itching. Both itch and rash diminished over next few days still mildly present 5/29/09.
Several children, ages 6-16, vax w/ booster dose;  complained of stinging at inject site;  stinging persisted for 1 minute.
A couple days after the second dose of Pfizer Covid19 vaccine, patient began experiencing stomach discomfort. After a couple days where the stomach pain intensified, felt nauseated and had diarrhea multiple times daily, patient was taken to the doctor (who performed blood tests and xray) and was told all tests were normal. On 6/17/2021, patient threw up three times, was unable to keep any food or fluids down so was taken to the emergency room for another check. Doctor at emergency room mentioned that it could be an adverse reaction between the growth hormone (Nutropin) patient is on and the Covid vaccine.
Passed out; This is a spontaneous report from a contactable consumer. This consumer reported for a male patient (nephew) reported that. A 30-years-old male patient received first dose of bnt162b2 (Pfizer covid vaccine, Solution for injection, Lot number was not reported),via an unspecified route of administration, administered in Arm on an unspecified date as 1st dose, single for covid-19 immunization. Medical history included allergy (to an unknown medication). The patient's concomitant medications were not reported. On an unknown date the patient experienced passed out. It was reported that the patient suddenly passed out and was rushed to the hospital after the first dose of the Pfizer covid vaccine. The patient is healthy and has an allergy to an unknown medication. The patient went to get the shot and then passed out. The patient passed out at the facility where he received the vaccine and was then rushed to the hospital and hospitalized. The caller is unsure when this event happened or the dates that the patient was hospitalized. The patient was released from the hospital the same day he was admitted. The caller mentions that the patient did not eat anything the day of the vaccine, prior to receiving the vaccine. The reporter asked Should the patient get the second dose of the vaccine. Is there any data on not eating all day and if that was an issue. The hospital ran all sorts of test on the patient and everything was fine. He had one shot he had one. And reporter wondering about getting the second one. The reporter stated, Okay, so I have a question about the Pfizer vaccine, so his 30 year old pretty much healthy nephew took the Pfizer vaccine and he passed out and they took him to the hospital (not clarified further if hospitalized or not, hence not captured in event tab) and ran bunch of test, he was fine, but he didn't eat all day. Do they have any data that shows if you don't eat all day you could have that kind of a reaction? Because the thing you know if is going to end up in the hospital I hate for him to have a second one you know what I mean, but if it is related to him not eating then that's another story. Well, I am wondering if they had data on anyone who had not eaten all day and whether or not there were reactions of that. Reporter was sure they tested every possibility when they tested this Pfizer vaccine. The patient underwent lab tests and procedures which included investigation: everything was fine. The event's seriousness was captured as hospitalized and medically significant. The clinical outcome of the event was unknown.
Info has been received from a Medical Assistant concerning a male pt in his mid-70's with hypertension and hypercholesterolemia who was vaccinated with a dose of pneumococcal vaccine 23 polyvalent (Lot #644218/1027M). Concomitant therapy was unspecified. Subsequently the pt developed swelling and redness at the injection site 24-48 hrs. post vaccination. Unspecified medical attention was sought. The reporter expressed concern with the lot. The medical assistant reported on another male pt (WAES #0301USA01827). The records of testing prior to release of this lot have been checked by Compliance and found to be satisfactory. The lot complies with the standards of the Center for Biologics Evaluation and Research and was released. No additional info is expected.
3RD DOSE PFIZER COVID VACCINE GIVEN 11/17/21, #FF8839; 4TH DOSE PFIZER COVID VACCINE GIVEN 4/14/22, #FK9893; BIVALENT COVID VACCINE GIVEN 9/13/22, #GH9694; Pt had a positive COVID test on 8/22/22 in SNF; hospice pt; pt passed away in the SNF
SICK; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (SICK) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriatic arthritis.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced ILLNESS (SICK). At the time of the report, ILLNESS (SICK) had resolved.            No concomitant medication was reported.   It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  No treatment information was provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Raised irregular shaped welts - No temp. - Itchy on parts of arm/legs and torso - Recommended BENADRYL _ See Dr. if not better.
COVID vaccine was administered by local health department in hospital setting.  Approximately 10 minutes after receiving the vaccine, the patient reports feeling "weird," short of breath, heart racing, dry mouth, & anxious.
I actually had my vaccine on 2/20/21 and had a gout attack 3 weeks later. On June 12 I had an appendicitis.
Swelling & redness at injection site.  Treated with BENADRYL & cool compresses, TYLENOL prn.
severe back pain, pelvic pain for one week and hard time walking.  irregular heart beat for 5 hours after the vaccine.
Lost complete bladder control for about 12 hours after having the booster / No matter how little "I" had in there or how much "I" tried to hold it in it just dribbled out; The patient received the third/booster dose of BNT162b2; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received the third (booster) dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2590) via an unspecified route of administration in the right arm on 31Oct2021 at 17:15 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. Medical history included migraines. The patient was allergic to some latex and sulfites. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included atenolol (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date and unknown if ongoing. The patient previously received sumatriptan succinate (IMITREX) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6201) via an unspecified route of administration in the left arm on 09Feb2021 at 16:00 (at the age of 67-years-old) and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 02Mar2021 at 16:00 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. On 31Oct2021 at 23:00, after having the booster, the patient lost complete bladder control for about 12 hours. It was also reported that no matter how little she had in there or how much she had tried to hold it in, it just dribbled out. The event did not result in a visit to the doctors or other healthcare professional office/clinic, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event lost complete bladder control for about 12 hours after having the booster / No matter how little "I" had in there or how much "I" tried to hold it in it just dribbled out was resolved on 01Nov2021 at 11:00.
Pt recv vax on 8/20/97; subsequently pt exp hyperpigmented cream-colored patch at vax site (3x3cm).
Participant stated she did not feel well, stated her tongue felt funny, thick, color was good, not short of breath, no throat swelling. Participant stated she had similar incident 10 yrs ago. BP 102/78 Pulse 78. Participant refused EPI injection. Was given BENADRYL.
Moderna COVID-19 Vaccine EUA Visible swelling tenderness, and pain in under arm lymph node on the same arm I received the vaccine.  This started 6 days after my first vaccine dose. I noticed it last night (March 30) before bed. I have some tingling and numbness as well as a cold feeling in my arm. I plan to monitor it and if the swelling does not subside or my symptoms get worse, I will seek medical attention.
test positive for covid; This spontaneous case was reported by a consumer and describes the occurrence of SARS-COV-2 TEST POSITIVE (test positive for covid) in a 59-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension and Prediabetes.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced SARS-COV-2 TEST POSITIVE (test positive for covid). At the time of the report, SARS-COV-2 TEST POSITIVE (test positive for covid) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       In concomitant medications hypertension medications were reported. Treatment details were Lemon water and tea with lemon reported.
This spontaneous report as received from a certified medical assistant refers to unspecified number of patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported. On unknown dates, the patients were vaccinated with the improperly stored doses of ROTATEQ (lot # L028645, expiration date 25-MAY-2017; dose was not reported). No adverse effects were reported. The vaccines were stored in 0.8 degrees of Celsius for 5 hours and 1 minute. Digital data logger was involved. No previous temperature excursion was reported. Additional information has been requested.
Headache, low grade fever, aches/pains, loss of appetite, fatigue, dizziness, nausea/vomiting - about 5 days
developed a firm tender lump at injection site. The area is improving- mild itching and soreness. No fever, chills, fatigue or malaise
fever; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever). At the time of the report, PYREXIA (fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.